Marianna Pina Rambaldi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marianna Pina Rambaldi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Caterina Serena
Department of Biomedical, Experimental and Clinical Sciences, Division of Obstetrics and Gynecology, University of Florence, Florence, Italy
2 shared publications - Federico Mecacci
Obstetrics and Gynaecology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy
2 shared publications - Serena Simeone
High Risk Pregnancy Unit, Careggi University Hospital, 50121 Florence, Italy
2 shared publications - Amerigo Vitagliano
Department of Women and Children's Health- AOU Careggi, Largo Brambilla, 3, Florence, Italy
1 shared publication - Chiara Franchi
Department of Fetal Medicine - AOU Careggi, Largo Brambilla, 3, Florence, Italy
1 shared publication Federico Mecacci
High Risk Pregnancy Unit, University Hospital of Careggi, Florence, Italy
1 shared publication
Latest Publications
- 12 August 2016
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 29 (sup2) , 19
D4. MCA/UtA ratio at first observation is associated with birthweight in late onset IUGR
Introduction: MCA and uterine artery Doppler PI are commonly used in the evaluation of IUGR. Targets: This retrospective pilot study aims to investigate whether MCA/UtA ratio may identify adverse outcome in late onset IUGRs. A cohort of 69 pregnancies affected with late IUGR which underwent labor induction according to local protocols was retrospectively revised on the relationship between MCA/UtA ratio at first observation and the following adverse outcomes: cesarean section for nonreassuring fetal status, birthweight (expressed as percentile and continuous values, umbilical artery pH, NICU admission and Apgar score < 7 after 1 and 5 min. Results: The study population included 75.4% nulliparous women. Mean gestational age was 36.7 and 38.7 weeks’ gestation for diagnosis and induction, respectively. MCA/UtA ratio resulted significantly associated with a lower trend in birthweight, with a variation of 109.72 g for each unit considered (p = 0.040). The other outcomes considered showed no association. Conclusions: MCA/UtA ratio at first observation may be associated with lower birthweight in late onset IUGRs. Further prospective studies are expected.
- 12 August 2016
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 29 (sup2) , 19
D4. MCA/UtA ratio at first observation is associated with birthweight in late onset IUGR
Introduction: MCA and uterine artery Doppler PI are commonly used in the evaluation of IUGR. Targets: This retrospective pilot study aims to investigate whether MCA/UtA ratio may identify adverse outcome in late onset IUGRs. A cohort of 69 pregnancies affected with late IUGR which underwent labor induction according to local protocols was retrospectively revised on the relationship between MCA/UtA ratio at first observation and the following adverse outcomes: cesarean section for nonreassuring fetal status, birthweight (expressed as percentile and continuous values, umbilical artery pH, NICU admission and Apgar score < 7 after 1 and 5 min. Results: The study population included 75.4% nulliparous women. Mean gestational age was 36.7 and 38.7 weeks’ gestation for diagnosis and induction, respectively. MCA/UtA ratio resulted significantly associated with a lower trend in birthweight, with a variation of 109.72 g for each unit considered (p = 0.040). The other outcomes considered showed no association. Conclusions: MCA/UtA ratio at first observation may be associated with lower birthweight in late onset IUGRs. Further prospective studies are expected.
- 1 January 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 184, 132-134
Management of placental mesenchymal dysplasia associated with fetal anemia and IUGR
- 1 January 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 184, 132-134
Management of placental mesenchymal dysplasia associated with fetal anemia and IUGR
- 1 February 2014
- Published by Springer Nature in Reproductive Sciences
- Vol. 21 (2) , 167-182
Inherited and Acquired Thrombophilias
Thrombophilias represent an evolving story that continues to stir controversy for care providers and obstetrical patients. The predominant thrombophilic mutations include the factor V Leiden mutation, prothrombin gene mutation G20210A, methylene tetrahydrafolate reductase C667T, and deficiencies of the natural anticoagulants proteins C and S, and antithrombin. Prospective cohort studies have provided an accurate assessment of the risk of placenta-mediated complications posed by common inherited thrombophilic conditions. Acquired thrombophilic conditions consist of the antiphospholipid antibody syndrome (APAS) and hyperhomocysteinemia. Well-conducted, placebo-controlled, randomized trials have demonstrated no benefit of anticoagulation in women with recurrent pregnancy loss and inherited thrombophilia. The routine use of anticoagulation to prevent other placenta-mediated complications in the setting of inherited thrombophilia should be considered experimental until the results of adequate clinical trials are available. Heparin anticoagulation and antiplatelet therapies are the cornerstone of treatment of APAS in pregnancy.
- 1 February 2014
- Published by Springer Nature in Reproductive Sciences
- Vol. 21 (2) , 167-182
Inherited and Acquired Thrombophilias
Thrombophilias represent an evolving story that continues to stir controversy for care providers and obstetrical patients. The predominant thrombophilic mutations include the factor V Leiden mutation, prothrombin gene mutation G20210A, methylene tetrahydrafolate reductase C667T, and deficiencies of the natural anticoagulants proteins C and S, and antithrombin. Prospective cohort studies have provided an accurate assessment of the risk of placenta-mediated complications posed by common inherited thrombophilic conditions. Acquired thrombophilic conditions consist of the antiphospholipid antibody syndrome (APAS) and hyperhomocysteinemia. Well-conducted, placebo-controlled, randomized trials have demonstrated no benefit of anticoagulation in women with recurrent pregnancy loss and inherited thrombophilia. The routine use of anticoagulation to prevent other placenta-mediated complications in the setting of inherited thrombophilia should be considered experimental until the results of adequate clinical trials are available. Heparin anticoagulation and antiplatelet therapies are the cornerstone of treatment of APAS in pregnancy.